InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.14
(
-0.30%
)
Bitcoin
63,596.59
(
-1.01%
)
Post# of 252311
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119895
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 214405

Tuesday, 10/31/2017 10:23:02 AM

Tuesday, October 31, 2017 10:23:02 AM

Post# of 252311
NVS submits Kymriah BLA in adult DLBCL (the indication for which GILD/KITE recently received FDA approval):

https://www.novartis.com/news/media-releases/novartis-submits-application-fda-kymriahtm-tisagenlecleucel-adult-patients-rr

Before year-end, NVS plans to submit EU MAAs for adult DLBCL and pediatric ALL (Kymriah’s already approved FDA indication).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up